Special Issue

Molecular Detection and Characterization of Multidrug Resistance in Staphylococci

Message from the Guest Editor

Staphylococci are a group of Gram-positive cocci and include coagulase-positive-most notably Staphylococcus aureus—and coagulase-negative staphylococci (CoNS). While some staphylococcal species are commensal organisms, others are major opportunistic or pathogenic threats with a formidable capacity to develop resistance to multiple antibiotic classes. The emergence and evolution of antibiotic resistance among staphylococci poses a major global public health challenge. S. aureus, in particular, has demonstrated remarkable adaptability, and multiple pandemic waves of methicillin-resistant S. aureus (MRSA) have occured. Similarly, CoNS, once considered clinically insignificant, have gained attention as important nosocomial pathogens and reservoirs for antimicrobial resistance genes. For this Special Issue, we invite the submission of original research articles, reviews, and short communications that address recent advances in the molecular detection and characterization of multidrug resistance in staphylococci. Contributions exploring staphyloccal resistance from clinical, animal, and environmental perspectives and presenting innovative methodologies and impactful findings are welcome.

Guest Editor

Prof. Dr. Kunyan Zhang

- 1. Departments of Pathology & Laboratory Medicine, of Microbiology, Immunology & Infectious Diseases, and of Medicine, University of Calgary, Calgary, AB, Canada
- 2. Centre for Antimicrobial Resistance, Alberta Health Services, Calgary, AB, Canada

Deadline for manuscript submissions

28 February 2026



an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/249943

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

